Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.

Saved in:

Bibliographic Details
Title:	Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
Authors:	de Almeida, Daniel Vargas P.^1,2, Anderson, Justine M.^1,3, Danila, Daniel C.^1,4, Morris, Michael J.^1,4, Slovin, Susan F.^1,4, Abida, Wassim^1,4, Cohn, Erica D.^1,5, Baser, Raymond E.⁶, Scher, Howard I.^1,4,7, Autio, Karen A.^1,4 AutioK@mskcc.org
Source:	Journal of Immunotherapy & Precision Oncology. Nov2023, Vol. 6 Issue 4, p162-169. 8p.
Database:	Academic Search Ultimate

Description
ISSN:	26662345
DOI:	10.36401/JIPO-23-9